Articles

Prediabetes has traditionally been diagnosed during annual physical exams through fasting glucose tests or A1C measurements. However, new diabetes prevention tools and wearable technologies are rapidly changing that model. Today, wearable devices, continuous glucose monitors (CGMs), and predictive metabolic tracking tools are giving people real-time insight into their glucose patterns …

Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults. While metformin has long served as the standard first-line therapy, many clinicians are now reconsidering whether a “metformin-first and wait” strategy is enough for this higher-risk population. As research continues …

Diabetic retinopathy remains one of the leading causes of preventable blindness worldwide. Yet despite clear screening guidelines, many patients with diabetes still miss their annual retinal exams. Busy schedules, limited specialist access, transportation barriers, and lack of awareness often delay diagnosis until vision changes become permanent. As healthcare systems search …

Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose …

New advances in diabetes technology are moving beyond glucose alone. While continuous glucose monitoring transformed diabetes management over the last decade, wearable ketone monitoring systems are now emerging as the next major innovation. Researchers, device manufacturers, and international diabetes organizations are increasingly focused on whether real-time ketone data can help …

A patient arrives at the pharmacy expecting their usual insulin refill, only to discover the box, brand name, and pen device suddenly look different. The pharmacist explains that the medication is an interchangeable biosimilar approved for automatic substitution. Although the insulin is considered clinically equivalent, the unexpected switch can still …

Managing Type 2 diabetes used to follow a relatively predictable path. Clinicians often started with metformin and added medications gradually as glucose control worsened. Today, however, diabetes care looks very different. The number of available therapies has expanded rapidly, and while that growth has improved patient outcomes, it has also …

Diabetes screening has improved over the last two decades, yet many patients still fall through the cracks. While clinicians often rely on traditional risk models that focus on obesity, age, family history, and sedentary lifestyle, not every patient with diabetes fits that familiar picture. As a result, many diabetes cases …

Improving hemoglobin A1C has long been considered the gold standard in diabetes care. However, many clinicians now question whether lower numbers always translate into healthier, happier patients. The growing debate over how A1C levels relate to real-world diabetes outcomes highlights an important issue in modern medicine: a patient can achieve …

Everything seems to be working perfectly until it suddenly isn’t. A patient is losing weight steadily, HbA1c levels are improving, and confidence is high during every follow-up visit. Then progress slows. The scale barely changes. Blood sugar readings stop improving. Patients start asking whether the medication has stopped working, while …